NCT07459660

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: MapLight Therapeutics · Industry
• Sex: All
• Age: 55 Years – 91 Years
• Healthy volunteers: Not accepted

Summary

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Conditions

• Psychosis Associated With Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	ML-007C-MA	ML-007C-MA dosed as 105/1.5 mg BID or 210/3 mg BID

Timeline

• Start date: 2026-03-25
• Primary completion: 2029-03-01
• Completion: 2029-03-01
• First posted: 2026-03-10
• Last updated: 2026-04-14

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study